Life Sciences Deal-Making Gets Creative Aims At Early Stages Amid COVID-19
Life Sciences Deal-Making Gets Creative, Aims At Early Stages Amid COVID-19 By Jeff Stoll and Kristin Pothier Life sciences companies remain unabated when it comes to creatively making deals during the COVID-19 pandemic, particularly among those targeting biopharma companies with early-stage assets. In the KPMG 2021 Healthcare & Life Sciences Investment Outlook, we tallied 1,138 acquisitions, licensing, and R&D deals announced in 2020, an increase from 634 in 2019. In 2020, we saw 121 company acquisitions globally versus 79 in 2019. The dollar value of the deals was smaller than in 2019, b...